Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P16 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P16.02 - Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience
00:00 - 00:00 | Presenter: Samantha Larna Dean
- Abstract
Loading...
-
+
ES02 - Multidisciplinary Collaboration in the Treatment of Oligometastatic Disease*
- 08:15 - 08:50
- 9/10/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Education Session
- Track: Multimodality of Advanced Lung Cancer
*Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.- Moderators:Fiona Mary Alison McDonald, Gerry Hanna
-
+
ES02.04 - Systemic Therapy Influenced Trials in Oligometastatic Disease
08:21 - 08:23 | Presenter: Paul Leslie Ross Mitchell
- Abstract
Loading...
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
18:55 - 19:05 | Presenter: Pasi A. Janne
- Abstract
Loading...
